Jonathan Ellant
Ophthalmology · New York, NYNPI 1306918669
Payments from drug & device makers
Across 333 payments — averaging $203.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$34K
- AbbVie$17K
- Rxsight Inc$3K
- Johnson & Johnson Surgical Vision, Inc.$3K
- Ivantis, Inc$3K
- Tarsus Pharmaceuticals, Inc.$2K
- plus $6K from 24 others
What the payments were for
- Consulting fees$16,95738%
- Speaking & faculty fees$16,43237%
- Travel & lodging$1290%
- Food & beverage$11,11725%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 36 | $33,875 |
| AbbVie(2 entities) | 72 | $16,634 |
| Rxsight Inc | 7 | $2,948 |
| Johnson & Johnson Surgical Vision, Inc. | 16 | $2,835 |
| Ivantis, Inc | 8 | $2,701 |
| Tarsus Pharmaceuticals, Inc. | 16 | $2,424 |
| Alcon | 28 | $1,119 |
| Sun Pharmaceutical Industries Inc. | 25 | $633 |
| Harrow Eye, LLC | 17 | $564 |
| Sight Sciences, Inc. | 6 | $532 |
| Mallinckrodt Hospital Products Inc. | 19 | $458 |
| Novartis | 16 | $370 |
| Lensar, Inc. | 1 | $358 |
| Bausch & Lomb Americas Inc. | 14 | $349 |
| Oyster Point Pharma, Inc. | 13 | $329 |
| NEW World Medical,inc. | 3 | $321 |
| Aerie Pharmaceuticals, Inc. | 6 | $221 |
| Ocular Therapeutix, Inc. | 2 | $199 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $192 |
| Amgen | 7 | $166 |
| Kala Pharmaceuticals, Inc. | 8 | $158 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $146 |
| Carl Zeiss Meditec, Inc. | 1 | $60 |
| Biotissue Holdings Inc. | 2 | $46 |
| Astellas Pharma US Inc | 1 | $30 |
| Dompe US, Inc. | 1 | $27 |
| Alimera Sciences, Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $24 |
| Thea Pharma Inc. | 1 | $18 |
| Akorn Operating Company LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS$11,673
- RESTASIS MULTIDOSE$3,391
- RXSIGHT CONTACT LENS$2,750
- RXSIGHT INJECTOR CARTRIDGE$2,750
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,750
- LIGHT ADJUSTABLE LENS (LAL)$2,750
- RXSIGHT INJECTOR HANDPIECE$2,750
- Hydrus Microstent$2,149
- Tecnis Symfony IOL$1,932
- iStent inject Trabecular Micro-Bypass Stent System$1,661
- Hydrus$472
- iDose$365
- LENSAR LASER SYSTEM$358
- OMNI(R) SURGICAL SYSTEM (US)$283
- iStent Trabecular Micro-Bypass System Model iS3$221
- iDoseTR$204
- DEXTENZA$185
- Unity$154
- Kahook Dual Blade$153
- Clearpath$153
How this compares
$67,778 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 165 | $184,438 |
| XiidraLifitegrast | 103 | $132,293 |
| LumiganBimatoprost | 73 | $45,502 |
| XdemvyLotilaner | 19 | $35,124 |
| RocklatanNetarsudil Mesylat/Latanoprost | 31 | $23,442 |
| Cyclosporine | 45 | $22,629 |
| CequaCyclosporine | 26 | $22,555 |
| MieboPerfluorohexyloctane/Pf | 20 | $14,630 |
| RhopressaNetarsudil Mesylate | 17 | $13,928 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $13,320 |
| TyrvayaVarenicline Tartrate | 14 | $13,197 |
| VyzultaLatanoprostene Bunod | 23 | $10,300 |
| Prednisolone Acetate | 349 | $9,810 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 23 | $7,862 |
| MoxifloxacinMoxifloxacin Hcl | 213 | $4,852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $16,634 | $243,260269 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $349 | $157,223146 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $221 | $37,37148 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,424 | $35,12419 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $633 | $22,55526 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $329 | $13,19714 claims |
| AlconSimbrinza | $1,119 | $7,86223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.